Scholarlink

<p>Binge eating disorder (BED) is the most common specific eating disorder. Mental health disorders and obesity commonly co-occur with BED. Treatment of these co-occurring conditions should be considered when selecting pharmacological treatments for BED, as some agents may have overlapping effectiveness. Lisdexamfetamine (LXD), an anti-attention deficit hyperactivity disorder treatment, is the only approved pharmacological agent for the treatment of moderate-to-severe BED. If LXD is not available, off-label treatment with topiramate, atomoxetine, sertraline or citalopram should be considered. Glucagon-like peptide receptor agonists have demonstrated potential for treatment of patients with co-occurring obesity and BED, although more research is required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider co-occurring conditions when selecting pharmacological treatment options for binge eating disorder

  • 期刊论文

  • 发表日期：

    2025年6月21日

查看全文
  • Michael B. Brown

摘要

Binge eating disorder (BED) is the most common specific eating disorder. Mental health disorders and obesity commonly co-occur with BED. Treatment of these co-occurring conditions should be considered when selecting pharmacological treatments for BED, as some agents may have overlapping effectiveness. Lisdexamfetamine (LXD), an anti-attention deficit hyperactivity disorder treatment, is the only approved pharmacological agent for the treatment of moderate-to-severe BED. If LXD is not available, off-label treatment with topiramate, atomoxetine, sertraline or citalopram should be considered. Glucagon-like peptide receptor agonists have demonstrated potential for treatment of patients with co-occurring obesity and BED, although more research is required.